March 11, 2025

Doctors Never Truly Vacation, Study Reveals

"Organizations should implement strategies to minimize clinical tasks during PTO."

Conexiant

March 10, 2025

Missing the Brain-Bladder Connection

New research emphasizes early detection of underlying neurologic conditions can improve outcomes for patients presenting with lower urinary tract symptoms

Conexiant

March 10, 2025

ACS Awards Dr. W. Kimryn Rathmell the 2025 Medal of Honor

Dr. Rathmell is a renowned kidney cancer expert with numerous achievements in translational research and treatment of complex and hereditary kidney cancers; most recently, she served as the 17th Direc...

The ASCO Post

March 10, 2025

Lower HCQ Dose Maintains Lupus Remission, Study Finds

With the use of Hydroxychloroquine at stable doses of 200 mg/day, more than 70% of inception patients with systemic lupus erythematosus in our cohort achieved prolonged remission.

Conexiant

March 07, 2025

Cabozantinib Improves PFS in Advanced Neuroendocrine Tumors

Cabozantinib significantly reduced disease progression risk in patients with advanced neuroendocrine tumors: A 62% lower risk in extrapancreatic NETs and 77% in pancreatic NETs, study authors report.

Conexiant

March 06, 2025

An Estimated 31 Million Americans Borrowed for Medical Bills in 2024

A new West Health-Gallup Survey survey reveals insights into medical debt across all income levels and demographics in the United States.

Conexiant

March 06, 2025

Medical Oddities: Bad Surgery Days, Risky Ink & Cancer-Fighting Tea

Maybe skip the Friday surgery slot to avoid risks. Study suggests we should think before getting ink. Tiny water bears see a big cancer treatment win, and more this week!

Conexiant

March 05, 2025

FDA Monthly Round-Up: Key February Updates

February's FDA approvals feature advancements in cardiology, neurology, infectious diseases, and rare disorders, including the first trials for genetically modified pig kidney transplants and novel treatments for Parkinson’s disease and spinal muscular atrophy.

Conexiant

March 05, 2025

Trastuzumab Rezetecan in Advanced HER2-Positive NSCLC

In a Chinese phase II trial (HORIZON-Lung) reported in The Lancet Oncology, Li et al found that trastuzumab rezetecan, a novel antibody-drug conjugate, showed activity in patients with advanced HER2-p...

The ASCO Post